<DOC>
	<DOC>NCT02109497</DOC>
	<brief_summary>This study is designed to determine the pharmacokinetic (PK) profile of a single oral dose of caffeine and the effects that PBT2 has on the metabolism of caffeine in healthy volunteers.</brief_summary>
	<brief_title>Phase 1 Study to Determine the Effects of PBT2 on the Pharmacokinetic Profile of Caffeine</brief_title>
	<detailed_description>This study will be conducted with all participants receiving a dose of caffeine 100 mg on Day 1 followed by a 7 day washout period before commencing 5 consecutive days of PBT2 250 mg from Day 8 to 12 and a second dose of caffeine 100 mg on Day 12. Pharmacokinetic samples will be collected during after each dose of the study drugs, along with safety monitoring assessments.</detailed_description>
	<mesh_term>Caffeine</mesh_term>
	<criteria>Healthy males or females with a BMI between 19 and 30kg/m2 No clinically significant abnormalities Exposure to medications/drugs that interfere with metabolism of PBT2 including drugs that inhibit or induce CYP1A2 Use of caffeinecontaining beverages, supplements or alcohol Significant history of depression or other psychiatric illness Surgical or medical conditions which could significantly alter drug absorption, distribution, metabolism or excretion Unable to swallow capsules or tablets</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>